中重度银屑病 PASI100 应答率：系统文献回顾及临床实践指南分析。
PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines.
机构信息
Department of Dermatology, Hospital General Universitario de Alicante-ISABIAL-UMH, Alicante, Spain.
Department of Dermatology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-IP), Madrid, Spain.
出版信息
J Dermatolog Treat. 2022 May;33(3):1661-1669. doi: 10.1080/09546634.2021.1890683. Epub 2021 Feb 21.
BACKGROUND
Response to treatments in psoriasis can be assessed using the PASI response 50, 75, 90 or 100. Achieving a PASI 100 response would mean a complete resolution of the patient's basal lesions. Therefore, PASI 100 score has been increasingly used in the context of research, but its role in daily practice is currently controversial.
OBJECTIVE
(1) To analyze PASI 100 response rates to pharmacological treatments; (2) To examine clinical practice guidelines (CPGs) recommendations/comments on PASI 100.
METHODS
We conducted a systematic literature review (SLR). Selection criteria concerned patients with psoriasis, reporting PASI 100.
RESULTS
Overall, 65 studies were included. Patients on methotrexate achieved at 16 weeks a PASI 100 of 7.3%. For TNF inhibitors rates were: 3.7-11.1% at 12 weeks, 13.7-20% at 16 weeks, 10.7-24% at 24 weeks and 21.8-34.8% at 1 year. IL-17 inhibitors achieved 23.3-44% at 12 weeks, 44.3-57.2% at 16 weeks, 39.7-67.5% at 24 weeks and 41.4-67.5% at 1 year. And the reported by IL-12/23 inhibitors were 12%/23.8% at 12 weeks, 32.7%/50% at 16 weeks, 44% at 24 weeks and 41.8%/56.3% at 1 year. PASI 100 response is scarcely commented in the CPGs.
CONCLUSIONS
PASI 100 response rate is an endpoint fundamentally restricted to research.
背景
银屑病的治疗反应可以通过 PASI 反应 50、75、90 或 100 来评估。达到 PASI 100 反应意味着患者的基底病变完全缓解。因此，PASI 100 评分在研究中越来越被使用，但它在日常实践中的作用目前存在争议。
目的
（1）分析药物治疗的 PASI 100 反应率；（2）检查临床实践指南（CPG）对 PASI 100 的建议/评论。
方法
我们进行了系统文献回顾（SLR）。选择标准涉及报告 PASI 100 的银屑病患者。
结果
总共纳入 65 项研究。在 16 周时，接受甲氨蝶呤治疗的患者 PASI 100 为 7.3%。对于 TNF 抑制剂，在 12 周时的比例为 3.7-11.1%，在 16 周时为 13.7-20%，在 24 周时为 10.7-24%，在 1 年时为 21.8-34.8%。在 12 周时，IL-17 抑制剂达到 23.3-44%，在 16 周时为 44.3-57.2%，在 24 周时为 39.7-67.5%，在 1 年时为 41.4-67.5%。IL-12/23 抑制剂报告的比例为 12%/23.8%在 12 周时，在 16 周时为 32.7%/50%，在 24 周时为 44%，在 1 年时为 41.8%/56.3%。PASI 100 反应在 CPG 中很少被评论。
结论
PASI 100 反应率是一个基本仅限于研究的终点。
Zotero 插件